News & Events

Mirati, Amgen, Lilly and more race to the front line in KRAS-mutated NSCLC

Mirati, Amgen, Lilly and more race to the front line in KRAS-mutated NSCLC

Targeted Therapies for Kirsten Rat Sarcoma (KRAS) G12C Mutant Metastatic Non-Small-Cell Lung Cancers

Targeted Therapies for Kirsten Rat Sarcoma (KRAS) G12C Mutant Metastatic Non-Small-Cell Lung Cancers

AstraZeneca joins KRAS push in cancer with Chinese deal

AstraZeneca joins KRAS push in cancer with Chinese deal

Advancements in KRAS Inhibitor Treatment for Cancer: A Look at the Latest Developments

Advancements in KRAS Inhibitor Treatment for Cancer: A Look at the Latest Developments

Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations

Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations

Targeting KRAS in NSCLC: Recent Progress and New Approaches

Targeting KRAS in NSCLC: Recent Progress and New Approaches

Is Amgen's Lung Cancer Drug Lumakras Up to the Mark? FDA Briefing Raises Concerns

Is Amgen's Lung Cancer Drug Lumakras Up to the Mark? FDA Briefing Raises Concerns

Sabari Reviews KRAS G12C Inhibitors in NSCLC

Sabari Reviews KRAS G12C Inhibitors in NSCLC

Adagrasib's Efficacy Sustained in KRASG12C NSCLC

Adagrasib's Efficacy Sustained in KRASG12C NSCLC

AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS CHEMOTHERAPY DATA IN FIRST-LINE KRAS G12C NSCLC AT WCLC

AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS CHEMOTHERAPY DATA IN FIRST-LINE KRAS G12C NSCLC AT WCLC